CIK 0001111485 · Accelerated filer
RxSight, Inc.
Sign in to watch- Ticker
- RXST
- Exchange
- Nasdaq
- Industry
- Ophthalmic Goods
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943268801
- Phone
- 949-521-7822
- Business address
- 100 COLUMBIA STREET, SUITE 120, ALISO VIEJO, CA, 92656
- Former names
- CALHOUN VISION INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $117,951
- in 4 filings
Net −$117,951. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 86 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-05 | Goldshleger Ilya See remarks | Sale 10b5-1 | −1,087 | $38.83 | $42K | 47,159 |
| 2024-08-05 | Goldshleger Ilya See remarks | Sale 10b5-1 | −1,913 | $39.51 | $76K | 45,246 |
| 2024-08-05 | Goldshleger Ilya See remarks | Sale 10b5-1 | −1,827 | $39.04 | $71K | 43,419 |
| 2024-08-05 | Goldshleger Ilya See remarks | Sale 10b5-1 | −1,173 | $39.73 | $47K | 42,246 |
| 2024-07-15 | Thunen Shelley B See remarks | Option exercise | +16,505 | $4.34 | $72K | 30,443 |
| 2024-07-15 | Thunen Shelley B See remarks | Option exercise · Stock Option (right to buy) | −11,235 | 6,405 | ||
| 2024-07-15 | Thunen Shelley B See remarks | Option exercise · Stock Option (right to buy) | −5,270 | 1,387 | ||
| 2024-07-11 | Kurtz Ronald M MD President & CEO | Option exercise | +13,500 | $15.08 | $204K | 53,500 |
| 2024-07-11 | Kurtz Ronald M MD President & CEO | Option exercise · Stock Option (right to buy) | −13,500 | 26,836 | ||
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Option exercise 10b5-1 | +10,000 | $15.60 | $156K | 23,938 |
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Sale 10b5-1 | −8,146 | $58.41 | $476K | 15,792 |
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Sale 10b5-1 | −1,854 | $59.48 | $110K | 13,938 |
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Sale 10b5-1 | −6,599 | $58.55 | $386K | 1,803 |
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Sale 10b5-1 | −1,803 | $59.56 | $107K | 0 |
| 2024-07-01 | Thunen Shelley B Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 36,805 | ||
| 2024-06-14 | Andrews Julie Director | Sale 10b5-1 | −11,940 | $57.84 | $691K | 33,972 |
| 2024-06-14 | Andrews Julie Director | Sale 10b5-1 | −3,685 | $58.53 | $216K | 30,287 |
| 2024-06-06 | Warner Robert Keith Director | Grant or award | +2,554 | 30,287 | ||
| 2024-06-06 | PALMISANO ROBERT J Director | Grant or award | +2,554 | 30,287 | ||
| 2024-06-06 | Maniar Shweta Director | Grant or award | +2,554 | 14,684 |
Page 11 of 15 · 300 trades